AMGN (Amgen Inc) Wutah bathi saben saham ing taun iki

Simbol resmi perusahaan Amgen Inc (AMGN)

Amgen Inc. maintains a stable revenue balance by focusing on updating its patent portfolio and R&D. The year-over-year change in EPS illustrates this resilience, which is supported by the non-cyclical nature of the biotech sector. Profit growth is driven by oncology and the drug MariTide, while the 7.80 metric confirms the issuer's current level of financial strength.

AMGN Wutah bathi saben saham ing taun lumaku Amgen Inc (04.07.2022 - 14.11.2026)

Rincian metrik keuangan lan pasar amgen.com (AMGN)

- rega saham lan konsensus proyeksi valuasi:
Bagan rega Amgen Corporation|AMGN - Prakiraan konsensus analis
- indikator valuasi pasar bisnis:
Kapitalisasi pasar Amgen|AMGN - Nilai Perusahaan
- informasi kapitalisasi buku:
Aset Bersih saben Saham Amgen|AMGN - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Nilai Buku amgen.com|AMGN - Total Aset Perusahaan
- indikator beban utang lan likuiditas:
Rasio Utang marang Modal Amgen Inc.|AMGN - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Amgen Corp|AMGN - Utang perusahaan|Utang marang nilai buku Amgen|AMGN - Utang jangka dawa perusahaan|Tanggungan jangka cendhak Amgen|Likuiditas darurat amgen.com
- data bathi lan kelipatan valuasi:
AMGN - Bathi resik perusahaan|Prakiraan bathi resik Amgen Inc.|AMGN - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi Amgen Inc.|AMGN - Pangali PEG|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Amgen Inc.|AMGN - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone 12 wulan pungkasan Amgen|AMGN - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan amgen.com|AMGN - Wutah bathi resik saben saham ing taun iki|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Amgen Inc.
- data pendapatan lan penerimaan dodolan:
AMGN - Pendapatan lan volume dodolan|Prakiraan volume dodolan Amgen Inc|AMGN - Rasio rega marang pendapatan|Multiplikator forward rega marang pendapatan Amgen
Analisis dhasar perusahaan:AMGN, Amgen Corporation
Produk asli Amgen Inc.

Stable demand for vital biologics makes Amgen Inc. (AMGN) a resilient defensive asset with predictable cash flows. By analyzing the annual EPS growth trajectory, an investor can track the change in net income per share relative to the previous year, allowing for an assessment of business scaling efficiency and confirming the issuer's fundamental reliability without the risk of overpaying for the asset.

Pesaing langsung

Wutah bathi saben saham ing taun iki LLY|ABBV (AbbVie) - Wutah bathi ing taun lumaku|astrazeneca.com (AZN) - Prakiraan wutah bathi resik saben saham ing taun iki|Wutah bathi saben saham ing taun lumaku Novartis Inc. (NVS)|Merck - Wutah bathi saben saham ing taun iki|Wutah bathi ing taun lumaku NVO (Novo Nordisk AS)|Owah-owahan bathi resik saben saham ing taun lumaku Pfizer Corp|SNY - Wutah bathi saben saham ing taun lumaku|BMY: Wutah bathi saben saham ing taun lumaku|GSK plc (GSK) - Wutah bathi saben saham ing taun lumaku|Takeda Pharmaceutical Company (TAK) - Wutah bathi ing taun lumaku|TEVA (tevapharm.com) - Wutah bathi ing taun lumaku|Dr. Reddy's Laboratories (RDY) - Prakiraan wutah bathi resik saben saham ing taun iki|Wutah bathi ing taun lumaku VTRS|Prakiraan wutah bathi resik saben saham ing taun iki Roivant Sciences|Zai Lab - Wutah bathi resik saben saham ing taun iki|BHC - Wutah bathi resik saben saham ing taun iki|COSM - Wutah bathi saben saham ing taun lumaku